Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Feb 09, 2026
UBS vs HSBC: Earnings Preview as Q4 Results Could Shift European Bank Sentiment

UBS vs HSBC: Earnings Preview as Q4 Results Could Shift European Bank Sentiment

Key Takeaways

  • UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY.

  • UBS has beat EPS estimates in the last four quarters by an average of 53%, driven by wealth management inflows and cost savings from Credit Suisse integration.

  • HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.

  • Both banks target mid-teens RoTE, with UBS advancing Credit Suisse integration, and HSBC focusing on Asia wealth expansion and cost discipline.

  • UBS emphasizes Swiss precision in wealth and investment banking, while HSBC leverages global scale, especially in Hong Kong and Asia.

  • Investor focus: UBS on integration milestones, HSBC on NII trajectory amid evolving interest rates.

Earnings Context and Why It Matters

UBS’s Q4 report closes a transformative year post-Credit Suisse acquisition, with investors monitoring progress on $13 billion in gross cost savings and non-core asset wind-downs. Despite a revenue dip from elevated prior-year levels, EPS growth is expected, supported by strong wealth inflows and a rebound in investment banking.

HSBC’s Q4 report highlights a different strategy: a global universal bank with a strong Asian focus. Comparing UBS and HSBC underscores diverging paths in European banking—UBS’s wealth-centric Swiss model versus HSBC’s diversified, Asia-driven approach. Both face geopolitical and interest rate pressures, but UBS’s integration execution and HSBC’s NII expansion showcase sector resilience, providing investors insight into European banking stability amid global volatility.

UBS: Earnings in Focus

  • Consensus EPS: $0.25–$0.67 (TipRanks median $0.54) vs. $0.23 last year.

  • Revenue: ~$11.62 billion, down YoY.

  • Key metrics:

    • Global Wealth Management net new assets (Q3: $38B quarterly)

    • Cumulative cost savings: $9.1B toward $13B target

    • CET1 ratio: ~14%

    • Non-Core/Legacy RWA reduction: Target < $8B by 2025-end

Investment banking revenues may benefit from solid Q4 deal flow. Historically, UBS has beat estimates by 53% on average, with stock reactions mixed (e.g., -2% post-Q3). Management guidance emphasizes completion of 2026 integration, supporting a ~15% RoCET1 target.

HSBC: Context and Earnings Relevance

  • Q4 consensus EPS: ~$1.57 vs. $1.45 prior.

  • Q3 highlights: Revenue $17.9B (+3% YoY), pre-tax profit $7.3B despite $1.4B legal provisions, NII +15% to $8.8B, and YTD RoTE 17.6% ex-notables.

  • Strategy emphasizes four core businesses (Hong Kong, UK, CIB, Wealth/Premier), mid-single-digit cost growth, and Hang Seng privatization.

  • HSBC’s emerging market exposure contrasts with UBS’s premium Swiss wealth focus. Both prioritize capital returns through dividends and buybacks.

Head-to-Head Earnings and Market Comparison

  • Scale and focus: HSBC ~$63B trailing revenue vs. UBS ~$39B, but UBS delivers higher margins in wealth management (Q3 NNA $92B YTD) vs. HSBC’s volume-driven growth.

  • Earnings quality: UBS average EPS surprise 53%, HSBC consistently strong ex-notables.

  • Growth drivers: UBS’s Credit Suisse synergies (70% of cost saves achieved); HSBC’s Asia pivot (wealth fees double-digit medium-term growth).

  • Risks: UBS faces legacy litigation and integration challenges; HSBC contends with property exposure (Hang Seng NPLs).

  • Valuation and sentiment: UBS trades at a premium, reflecting transformation progress, while HSBC remains a steady execution play amid interest rate sensitivity.

Tickeron AI Perspective

Tickeron AI Verdict

Tickeron’s AI models currently favor UBS, citing:

  • Superior earnings surprise history

  • Accelerating cost efficiencies

  • Positioned growth in high-margin wealth and investment banking

HSBC offers scale and NII resilience, but UBS’s integration execution and RoCET1 trajectory give it a probabilistic edge for outperformance, assuming no major shocks.

Disclaimers and Limitations

Related Ticker: UBS, HSBC

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


UBS's RSI Oscillator ascending out of oversold territory

The RSI Indicator for UBS moved out of oversold territory on October 02, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 24 similar instances when the indicator left oversold territory. In 21 of the 24 cases the stock moved higher. This puts the odds of a move higher at 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a +1.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where UBS advanced for three days, in 234 of 350 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.

UBS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 14, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on UBS as a result. In 38 of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 49%.

The Moving Average Convergence Divergence Histogram (MACD) for UBS turned negative on September 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 19 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 46%.

UBS moved below its 50-day moving average on September 14, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for UBS crossed bearishly below the 50-day moving average on September 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 6 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 35%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where UBS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.

The Aroon Indicator for UBS entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 5 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 13 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 21, placing this stock better than average.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 54 (best 1 - 100 worst), indicating fairly steady price growth. UBS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 57 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.669) is normal, around the industry mean (1.866). P/E Ratio (16.537) is within average values for comparable stocks, (14.888). Projected Growth (PEG Ratio) (0.669) is also within normal values, averaging (2.139). Dividend Yield (0.023) settles around the average of (0.026) among similar stocks. P/S Ratio (3.209) is also within normal values, averaging (3.867).

The Tickeron PE Growth Rating for this company is 69 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are JPMorgan Chase & Co (NYSE:JPM), Bank of America Corp (NYSE:BAC), HSBC Holdings PLC (NYSE:HSBC), Wells Fargo & Co (NYSE:WFC), Citigroup (NYSE:C), Barclays PLC (NYSE:BCS).

Industry description

Major banks are among the biggest companies in the world, often times with global reach and market capitalizations in the multi-billions. Large banks often have multiple arms spanning different disciplines, from deposits, to investment banking, to wealth management and insurance. The biggest banks often have key competitive advantages over smaller players in the industry in terms of brand recognition, cost of capital, and efficiency. Think J.P. Morgan, Bank of America, Wells Fargo, and Citigroup.

Market Cap

The average market capitalization across the Major Banks Industry is 206.84B. The market cap for tickers in the group ranges from 1.04M to 894.72B. JPM holds the highest valuation in this group at 894.72B. The lowest valued company is BACRP at 1.04M.

High and low price notable news

The average weekly price growth across all stocks in the Major Banks Industry was -2%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was 14%. FRBT experienced the highest price growth at 3%, while BBVA experienced the biggest fall at -6%.

Volume

The average weekly volume growth across all stocks in the Major Banks Industry was 17%. For the same stocks of the Industry, the average monthly volume growth was 49% and the average quarterly volume growth was -22%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 68
P/E Growth Rating: 33
Price Growth Rating: 48
SMR Rating: 4
Profit Risk Rating: 21
Seasonality Score: 52 (-100 ... +100)
View a ticker or compare two or three
UBS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a major bank

Industry MajorBanks

Industry
Major Banks
Address
Bahnhofstrasse 45
Phone
+41 442341111
Employees
105236
Web
https://www.ubs.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
GE Aerospace (GE) stock declined -12% over the past 30 days, falling from around $333 to $293, amid profit-taking after record highs near $348. Over the past quarter, the stock is down -8%, reflecting post-earnings selloff despite strong Q4 2025 results with 20% revenue growth.
Toyota Motor Corporation (TM) stands as the world's largest automaker by volume, designing, manufacturing, and selling a wide range of vehicles—from sedans and trucks to SUVs and electrified models like hybrids—under brands including Toyota, Lexus, and Daihatsu. The company's business model centers on a robust global supply chain, vertical integration in components like engines and transmissions, and a multi-pathway approach that prioritizes hybrids alongside EVs and hydrogen technology. In the highly competitive automotive sector, Toyota maintains a strong position, particularly with its dominant hybrid market share, though it faces mounting pressure from EV frontrunners such as BYD in China and Tesla worldwide. From what I see, these core strengths explain much of the recent stock action: the resilience from hybrids offers some stability, but the slower EV rollout and heavy China exposure heighten sales volatility in a shifting market.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
Sable Offshore Corp. (SOC) shares fell 7.40% in the most recent completed session, closing at $16.52 versus a prior close of $17.84. The pullback followed a volatile stretch in which SOC traded between $15.76 and $19.21 over just two sessions, reflecting profit‑taking after a strong run in March.
NBR stock rose approximately +12% over the last 30 days, driven by positive momentum in the oil and gas drilling sector and strong Q4 earnings beat. Over the past quarter, the stock surged +58%, fueled by robust YTD performance, debt reduction efforts, and improved operational results in international drilling.
Patterson-UTI Energy, Inc. (PTEN) stands out as a leading provider of drilling and completion services to oil and natural gas exploration and production companies, primarily in the United States and select international markets. The company operates through three main segments: Drilling Services, which includes contract drilling rigs and directional drilling; Completion Services, encompassing hydraulic fracturing, wireline, and pumping; and Drilling Products, offering specialized drill bits globally, including in the Middle East.
As a provider of onshore drilling and completion services, Patterson-UTI Energy (PTEN) is gearing up for a key Q1 2026 earnings report against the backdrop of fluctuating oil prices and steady U.S. rig demand. The company's integrated approach across Drilling Services, Completion Services, and Drilling Products gives it a solid footing in North American shale plays. In my view, recent quarters like Q4 2025, where revenue exceeded estimates despite a net loss, highlight its resilience. This upcoming report will offer insights into activity levels, margin trends, and capital discipline amid supply growth and geopolitical tensions. With strong free cash flow and recent dividend increases, PTEN's focus on shareholders stands out, making this a critical gauge for the 2026 outlook in the cyclical oilfield services sector.
When geopolitical turmoil sends markets into chaos, most retail traders freeze — but Tickeron's Energy (OXY, EOG, DVN, FANG, APA, MTDR) AI Trading Agent is built to thrive in exactly these conditions. This 15-minute and 60-minute AI-powered robot has delivered a +76.22% annualized return with a 64.21% win rate and a Profit Factor of 2.70 — trading six of the most volatile and opportunity-rich energy tickers on the market.
The global energy sector is on fire — literally and figuratively. With crude oil prices swinging 20–30% in response to geopolitical flashpoints, OPEC+ production cuts, and escalating conflicts in Eastern Europe and the Middle East, traders who aren't using AI-powered tools are flying blind. Enter Tickeron's Energy (Oil & Gas – E&P) AI Trading Agent — a 60-minute signal robot built exclusively around five high-impact Exploration & Production tickers, now posting a staggering +49% Annualized Return and +1,251% 30-Day Annualized Return, with $14,703 in closed-trade P&L on a $30,000 simulated balance.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.